METHOD FOR PREDICTING THE RESPONSE AND SURVIVAL FROM CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 1, 2016
app pub date -
Feb 11, 2015
filing date -
Feb 11, 2015
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A method predicts the residual risk of recurrence after a taxane-free chemotherapy, and the benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent breast cancer. From determination of expression levels of the genes UBE2C, KIF20A, PTGER3, OSBPL1A, CYP27A1, IGKC, in a tumor sample a prognostic score is determined by mathematically combining the expression level values. The prognostic score is compared to thresholds, classifying the patient in three outcome groups. The expression levels of three genes STC1, PCSK6, S100P in the tumor sample are determined, and the expression level values for STC1, PCSK6 and S100P are mathematically combined to yield a predictive combined score, whereas a high predictive combined score generally indicates an increased likelihood of benefit from inclusion of taxane in a chemotherapy regimen in a patient classified to poor and/or intermediate outcome group.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully